deferasirox teva slovakia 500 mg
teva b.v., holandsko - deferasirox - 19 - antidota, detoxicantia
deferasirox teva slovakia 250 mg
teva b.v., holandsko - deferasirox - 19 - antidota, detoxicantia
deferasirox teva slovakia 125 mg
teva b.v., holandsko - deferasirox - 19 - antidota, detoxicantia
explemed rapid 30 mg
egis pharmaceuticals plc, maďarsko - aripiprazol - 68 - antipsychotica (neuroleptica)
explemed rapid 15 mg
egis pharmaceuticals plc, maďarsko - aripiprazol - 68 - antipsychotica (neuroleptica)
explemed rapid 10 mg
egis pharmaceuticals plc, maďarsko - aripiprazol - 68 - antipsychotica (neuroleptica)
explemed rapid 5 mg
egis pharmaceuticals plc, maďarsko - aripiprazol - 68 - antipsychotica (neuroleptica)
omarit 10 mg orodispergovateľné tablety
menarini international operations luxembourg s.a., luxembursko - bilastín - 24 - antihistaminica, histamin
adempas
bayer ag - riociguat - hypertenzia, pľúca - antihypertenzíva pre pľúcnu arteriálnu hypertenziu - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. Účinnosť bola preukázaná v pau obyvateľstva vrátane aetiologies z idiopatická alebo dedičné pau alebo pah spojené s spojivového tkaniva ochorenia. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.
cancidas (previously caspofungin msd)
merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimykotika na systémové použitie - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.